孟子延;马丹婧;高雪;李琦涵;

• 1:中国医学科学院北京协和医学院医学生物学研究所云南省重大传染病疫苗研发重点实验室

摘要(Abstract)：

目前,重症急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的新型冠状病毒病(Corona Virus Disease 2019,COVID-19)仍在全球迅速蔓延,给人类生活带来了巨大的健康隐患和经济负担,接种疫苗是预防和控制该病毒传播的重要途径。mRNA疫苗是将含有编码抗原蛋白的mRNA导入人体,直接进行翻译,形成相应的抗原蛋白,从而诱导机体产生特异性免疫应答,达到预防免疫的作用。mRNA疫苗是继灭活疫苗、减毒活疫苗、亚单位疫苗和病毒载体疫苗后的第三代疫苗,具有针对病原体变异反应速度快、生产工艺简单、易规模化扩大等特点。本文就mRNA疫苗的免疫学特性、分子设计、递送系统、安全性的研究进展及其相应机制作一综述。

关键词(KeyWords)： mRNA疫苗;重症急性呼吸综合征冠状病毒2;新型冠状病毒病;安全性

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划项目（2020YFC0849700）

作者(Authors): 孟子延;马丹婧;高雪;李琦涵;

DOI: 10.13200/j.cnki.cjb.003368

参考文献(References)：

• [1]MALONE R W,FELGNER P L,VERMA I M.Cationic liposome-mediated RNA transfection[J].Proc Natl Acad Sci USA,1989,86(16):6077-6081.
• [2]WOLFF J A,MALONE R W,WILLIAMS P,et al.Direct gene transfer into mouse muscle in vivo[J].Science,1990,247(4949 Pt 1):1465-1468.
• [3]PARDI N,HOGAN M J,PELC R S,et al.Zika virus protection by a single low-dose nucleoside-modified m RNA vaccination[J].Nature,2017,543(7644):248-251.
• [4]PARDI N,SECRETO A J,SHAN X,et al.Administration of nucleoside-modified m RNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge[J].Nat Commun,2017,8:14630.
• [5]CHAHAL J S,KHAN O F,COOPER C L,et al.DendrimerRNA nanoparticles generate protective immunity against lethal Ebola,H1N1 influenza,and Toxoplasma gondii challenges with a single dose[J].Proc Natl Acad Sci USA,2016,113(29):E4133-E4142.
• [6]MEYER M,HUANG E,YUZHAKOV O,et al.Modified m RNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease[J].J Infect Dis,2018,217(3):451-455.
• [7]PARDI N,LABRANCHE C C,FERRARI G,et al.Characterization of HIV-1 nucleoside-modified m RNA vaccines in rabbits and rhesus macaques[J].Mol Ther Nucleic Acids,2019,15:36-47.
• [8]SAHIN U,TURECI O.Personalized vaccines for cancer immunotherapy[J].Science,2018,359(6382):1355-1360.
• [9]THANH L T,ANDREADAKIS Z,KUMAR A,et al.The COVID-19 vaccine development landscape[J].Nat Rev Drug Discov,2020,19(5):305-306.
• [10]PROMPETCHARA E,KETLOY C,PALAGA T.Immune responses in COVID-19 and potential vaccines:Lessons learned from SARS and MERS epidemic[J].Asian Pac J Allergy Immunol,2020,38(1):1-9.
• [11]POLACK F P,THOMAS S J,KITCHIN N,et al.Safety and efficacy of the BNT162b2 m RNA Covid-19 vaccine[J].N Engl J Med,2020,383(27):2603-2615.
• [12]BADEN L R,EL S H,ESSINK B,et al.Efficacy and safety of the m RNA-1273 SARS-Co V-2 vaccine[J].N Engl J Med,2021,384(5):403-416.
• [13]VAN NUFFEL A M,BENTEYN D,WILGENHOF S,et al.Dendritic cells loaded with m RNA encoding full-length tumor antigens prime CD4+and CD8+T cells in melanoma patients[J].Mol Ther,2012,20(5):1063-1074.
• [14]KARIKO K,MURAMATSU H,LUDWIG J,et al.Generating the optimal m RNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleosidemodified,protein-encoding m RNA[J].Nucleic Acids Res,2011,39(21):e142.
• [15]KARIKO K,MURAMATSU H,LUDWIG J,et al.Generating the optimal m RNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleoside-modified,protein-encoding m RNA[J].Nucleic Acids Res,2011,39(21):e142.
• [16]KARIKO K,NI H,CAPODICI J,et al.m RNA is an endogenous ligand for Toll-like receptor 3[J].J Biol Chem,2004,279(13):12542-12550.
• [17]YONEYAMA M,KIKUCHI M,NATSUKAWA T,et al.The RNA helicase RIG-I has an essential function in doublestranded RNA-induced innate antiviral responses[J].Nat Immunol,2004,5(7):730-737.
• [18]HERVAS-STUBBS S,PEREZ-GRACIA J L,ROUZAUT A,et al.Direct effects of type I interferons on cells of the immune system[J].Clin Cancer Res,2011,17(9):2619-2627.
• [19]CHEN K,LIU J,CAO X.Regulation of type I interferon signaling in immunity and inflammation:A comprehensive review[J].J Autoimmun,2017,83:1-11.
• [20]ZHONG Z,MCCAFFERTY S,COMBES F,et al.m RNA therapeutics deliver a hopeful message[J].Nano Today,2018,23:16-39.
• [21]SAHIN U,KARIKO K,TURECI O.m RNA-based therapeutics--developing a new class of drugs[J].Nat Rev Drug Discov,2014,13(10):759-780.
• [22]KORMANN M S,HASENPUSCH G,ANEJA M K,et al.Expression of therapeutic proteins after delivery of chemically modified m RNA in mice[J].Nat Biotechnol,2011,29(2):154-157.
• [23]KARIKO K,MURAMATSU H,WELSH F A,et al.Incorporation of pseudouridine into m RNA yields superior nonimmunogenic vector with increased translational capacity and biological stability[J].Mol Ther,2008,16(11):1833-1840.
• [24]KORMANN M S,HASENPUSCH G,ANEJA M K,et al.Expression of therapeutic proteins after delivery of chemically modified m RNA in mice[J].Nat Biotechnol,2011,29(2):154-157.
• [25]SCHLAKE T,THESS A,FOTIN-MLECZEK M,et al.Developing m RNA-vaccine technologies[J].RNA Biol,2012,9(11):1319-1330.
• [26]GOODARZI H,NAJAFABADI H S,OIKONOMOU P,et al.Systematic discovery of structural elements governing stability of mammalian messenger RNAs[J].Nature,2012,485(7397):264-268.
• [27]KUDLA G,LIPINSKI L,CAFFIN F,et al.High guanine and cytosine content increases m RNA levels in mammalian cells[J].PLo S Biol,2006,4(6):e180.
• [28]SAMPLE P J,WANG B,REID D W,et al.Human 5′UTRdesign and variant effect prediction from a massively parallel translation assay[J].Nat Biotechnol,2019,37(7):803-809.
• [29]JIA L,MAO Y,JI Q,et al.Decoding m RNA translatability and stability from the 5′UTR[J].Nat Struct Mol Biol,2020,27(9):814-821.
• [30]TREPOTEC Z,ANEJA M K,GEIGER J,et al.Maximizing the translational yield of m RNA therapeutics by minimizing 5′-UTRs[J].Tissue Eng Part A,2019,25(1-2):69-79.
• [31]PONTRELLI L,SIDIROPOULOS K G,ADELI K.Translational control of apolipoprotein B m RNA:regulation via cis elements in the 5′and 3′untranslated regions[J].Biochemistry,2004,43(21):6734-6744.
• [32]PELLETIER J,SONENBERG N.Insertion mutagenesis to increase secondary structure within the 5′noncoding region of a eukaryotic m RNA reduces translational efficiency[J].Cell,1985,40(3):515-526.
• [33]ORLANDINI V N A,POLEGANOV M A,RECHNER C,et al.Improving m RNA-based therapeutic gene delivery by expression-augmenting 3′UTRs identified by cellular library screening[J].Mol Ther,2019,27(4):824-836.
• [34]JEMIELITY J,FOWLER T,ZUBEREK J,et al.Novel“antireverse”cap analogs with superior translational properties[J].RNA,2003,9(9):1108-1122.
• [35]KUHN A N,DIKEN M,KREITER S,et al.Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo[J].Gene Ther,2010,17(8):961-971.
• [36]KOWALSKA J,LEWDOROWICZ M,ZUBEREK J,et al.Synthesis and characterization of m RNA cap analogs containing phosphorothioate substitutions that bind tightly to e IF4E and are resistant to the decapping pyrophosphatase Dcp S[J].RNA,2008,14(6):1119-1131.
• [37]DEVARKAR S C,WANG C,MILLER M T,et al.Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I[J].Proc Natl Acad Sci USA,2016,113(3):596-601.
• [38]SCHUBERTH-WAGNER C,LUDWIG J,BRUDER A K,et al.A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-2′O-methylated self RNA[J].Immunity,2015,43(1):41-51.
• [39]VAIDYANATHAN S,AZIZIAN K T,HAQUE A,et al.Uridine depletion and chemical modification increase Cas9 m RNAactivity and reduce immunogenicity without HPLC purification[J].Mol Ther Nucleic Acids,2018,12:530-542.
• [40]CHEN Y H,COLLER J.A universal code for m RNA stability[J].Trends Genet,2016,32(11):687-688.
• [41]HOLTKAMP S,KREITER S,SELMI A,et al.Modification of antigen-encoding RNA increases stability,translational efficacy,and T-cell stimulatory capacity of dendritic cells[J].Blood,2006,108(13):4009-4017.
• [42]HOLTKAMP S,KREITER S,SELMI A,et al.Modification of antigen-encoding RNA increases stability,translational efficacy,and T-cell stimulatory capacity of dendritic cells[J].Blood,2006,108(13):4009-4017.
• [43]MOCKEY M,GONCALVES C,DUPUY F P,et al.m RNAtransfection of dendritic cells:synergistic effect of ARCA m RNAcapping with Poly(A)chains in cis and in trans for a high protein expression level[J].Biochem Biophys Res Commun,2006,340(4):1062-1068.
• [44]PARDI N,PARKHOUSE K,KIRKPATRICK E,et al.Nucleoside-modified m RNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies[J].Nat Commun,2018,9(1):3361.
• [45]SAHIN U,KARIKO K,TURECI O.m RNA-based therapeutics-developing a new class of drugs[J].Nat Rev Drug Discov,2014,13(10):759-780.
• [46]JOHANNING F W,CONRY R M,LOBUGLIO A F,et al.ASindbis virus m RNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo[J].Nucleic Acids Res,1995,23(9):1495-1501.
• [47]CONRY R M,LOBUGLIO A F,WRIGHT M,et al.Characterization of a messenger RNA polynucleotide vaccine vector[J].Cancer Res,1995,55(7):1397-1400.
• [48]HOERR I,OBST R,RAMMENSEE H G,et al.In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies[J].Eur J Immunol,2000,30(1):1-7.
• [49]ISLAM M A,REESOR E K,XU Y,et al.Biomaterials for m RNA delivery[J].Biomater Sci,2015,3(12):1519-1533.
• [50]JAYARAMAN M,ANSELL S M,MUI B L,et al.Maximizing the potency of si RNA lipid nanoparticles for hepatic gene silencing in vivo[J].Angew Chem Int Ed Engl,2012,51(34):8529-8533.
• [51]CHENG X,LEE R J.The role of helper lipids in lipid nanoparticles(LNPs) designed for oligonucleotide delivery[J].Adv Drug Deliv Rev,2016,99(Pt A):129-137.
• [52]WITTRUP A,AI A,LIU X,et al.Visualizing lipid-formulated si RNA release from endosomes and target gene knockdown[J].Nat Biotechnol,2015,33(8):870-876.
• [53]YANEZ A M,KJELLMAN T,BARTESAGHI S,et al.Successful reprogramming of cellular protein production through m RNA delivered by functionalized lipid nanoparticles[J].Proc Natl Acad Sci USA,2018,115(15):E3351-E3360.
• [54]JULIANO R L.Intracellular trafficking and endosomal release of oligonucleotides:What we know and what we don′t[J].Nucleic Acid Ther,2018,28(3):166-177.
• [55]PATEL S,ASHWANIKUMAR N,ROBINSON E,et al.Boosting intracellular delivery of lipid nanoparticle-encapsulated m RNA[J].Nano Lett,2017,17(9):5711-5718.
• [56]PHUA K K.Towards targeted delivery systems:Ligand conjugation strategies for m RNA nanoparticle tumor vaccines[J].JImmunol Res,2015,2015:680620.
• [57]DOMEIER P P,CHODISETTI S B,SCHELL S L,et al.B-cell-intrinsic type 1 interferon signaling is crucial for loss of tolerance and the development of autoreactive B cells[J].Cell Rep,2018,24(2):406-418.
• [58]WALSH S R,BASTIN D,CHEN L,et al.Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity[J].J Clin Invest,2019,129(2):518-530.
• [59]SEBASTIAN M,SCHRODER A,SCHEEL B,et al.A phase I/IIa study of the m RNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer[J].Cancer Immunol Immunother,2019,68(5):799-812.
• [60]GRECO A,GALLO A,FUSCONI M,et al.Bell′s palsy and autoimmunity[J].Autoimmun Rev,2012,12(2):323-328.
• [61]REPAJIC M,LAI X L,XU P,et al.Bell′s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell′s palsy[J].Brain Behav Immun Health,2021,13:100217.
• [62]XIA S,ZHANG Y,WANG Y,et al.Safety and immunogenicity of an inactivated SARS-Co V-2 vaccine,BBIBP-Cor V:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J].Lancet Infect Dis,2021,21(1):39-51.
• [63]ZHANG Y,ZENG G,PAN H,et al.Safety,tolerability,and immunogenicity of an inactivated SARS-Co V-2 vaccine in healthy adults aged 18-59 years:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J].Lancet Infect Dis,2021,21(2):181-192.
• [64]PALACIOS R,PATINO E G,DE OLIVEIRA P R,et al.Double-blind,randomized,placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV:A structured summary of a study protocol for a randomised controlled trial[J].Trials,2020,21(1):853.
• [65]KEECH C,ALBERT G,CHO I,et al.Phase 1-2 trial of a SARS-Co V-2 recombinant spike protein nanoparticle vaccine[J].N Engl J Med,2020,383(24):2320-2332.
• [66]RICHMOND P,HATCHUEL L,DONG M,et al.Safety and immunogenicity of S-Trimer(SCB-2019),a protein subunit vaccine candidate for COVID-19 in healthy adults:a phase 1,randomised,double-blind,placebo-controlled trial[J].Lancet,2021,397(10275):682-694.
• [67]FOLEGATTI P M,EWER K J,ALEY P K,et al.Safety and immunogenicity of the Ch Ad Ox1 n Co V-19 vaccine against SARS-Co V-2:a preliminary report of a phase 1/2,singleblind,randomised controlled trial[J].Lancet,2020,396(10249):467-478.
• [68]ZHU F C,GUAN X H,LI Y H,et al.Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19vaccine in healthy adults aged 18 years or older:a randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2020,396(10249):479-488.
• [69]RAMASAMY M N,MINASSIAN A M,EWER K J,et al.Safety and immunogenicity of Ch Ad Ox1 n Co V-19 vaccine administered in a prime-boost regimen in young and old adults(COV002):a single-blind,randomised,controlled,phase 2/3trial[J].Lancet,2021,396(10267):1979-1993.